NCT02530515View on ClinicalTrials.gov

Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 18, 2015

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
AnemiaCancer FatigueChronic Lymphocytic LeukemiaFeverInfectious DisorderLymphadenopathyLymphocytosisNight SweatsProlymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRichter SyndromeSecondary Malignant NeoplasmThrombocytopeniaWeight Loss
Interventions
BIOLOGICAL

Ex Vivo-activated Autologous Lymph Node Lymphocytes

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02530515 - Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter